Blinatumomab for paediatric mixed phenotype acute leukaemia

Mixed phenotype acute leukaemia (MPAL) is rare, comprising <5% of paediatric acute leukaemia.1 Prospective clinical trials are lacking, therefore there is no consensus about optimal treatment, although recent surveys by the United States Childhood Oncology Group (COG) and iBFM AMBI2012 registry have established that lymphoid directed treatment is associated with superior outcomes.1, 2 This is especially the case for patients with CD19-positive...